Evidence map›Paper›PMID 40432153›Full record

ArticleVaccines2025

XBB.1.5 RBD-Based Bivalent Vaccines Induced Antibody Responses Against SARS-CoV-2 Variants in Mice.

Jiawen Liu, Tiantian Wang, Hongying Ren, Ruixi Liu, Qian Wang, Jun Wu, Bo Liu

Abstract read
In one paragraph

Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jiawen LiuLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China.
Tiantian WangLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China.
Hongying RenLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China.
Ruixi LiuLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China.
Qian WangLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China.
Jun WuLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China.
Bo LiuLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China.ORCID 0000-0001-6655-1866

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Background: The currently circulating variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibits resistance to antibodies induced by vaccines. The World Health Organization recommended the use of monovalent XBB.1 sublineages (e.g., XBB.1.5) as an antigenic component in 2023. (2) Objective: In this study, we aimed to develop vaccines based on the XBB.1.5 receptor-binding domain (RBD) to combat the recently emerged SARS-CoV-2 XBB and JN.1 variants, as well as previously circulating variants. (3) Methods: Glycoengineered

Indexed as

bivalent vaccineglycoengineered yeastmonovalent vaccineRBDSARS-CoV-2subunit vaccine

Identifiers

PMID40432153
PMCPMC12115535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.